GLENMARK

’s 10-Year Pivot: From Generics Pioneer to Global Drug Innovator

is executing a major strategic pivot to transition from a traditional generics manufacturer into an innovation-led global pharmaceutical player. Chairman Glenn Saldanha emphasizes that this shift will be a gradual, long-term process requiring a high tolerance for research failures. The AbbVie Catalyst: The catalyst for this reset was a landmark July 2025 licensing deal between Glenmark’s US-based biotech unit, Ichnos Glenmark Innovation (IGI), and AbbVie for the blood cancer drug candidate ISB 2001. The deal brought an upfront payment of $700 million—with up to $1.225 billion in potential milestones—allowing Glenmark to wipe out its gross debt and validate its oncology research. Agile Global Competition: By establishing IGI as a nimble biotech entity in the US while leveraging cost-efficient operations in India, Glenmark is actively competing with established Western biotechs. The company is focusing heavily on the quality of its science rather than a high volume of random assets. Future Asset Pipeline: Moving forward, IGI plans to file one Investigational New Drug (IND) application every year, beginning with its solid-tumor candidate, ISB 2301, later this year. Additionally, a phase 1/2 combination study for ISB 2001 in multiple myeloma is scheduled for Q3 2026. A Dual-Engine Business Model: Glenmark will operate using two distinct commercial pillars: a stable, cash-generating global pharmaceutical and specialty business (covering respiratory, dermatology, and oncology) to self-fund its high-risk, long-term innovation engine. For future innovative assets, the company intends to retain commercial rights in India and emerging markets while seeking licensing partnerships in developed regions.